Table 9.
ITCs inhibit the in vivo growth of prostate tumors by inhibiting angiogenesis.
| ITC | Factor | Model (Cell Line) | Reference |
|---|---|---|---|
| PEITC | ≈ PECAM-1/CD31 | TRAMP | [12] |
| PEITC | ↓ PECAM-1/CD31 | Subcutaneous xenograft (LNCaP) | [148] |
| PEITC | ≈ VEGF | Subcutaneous xenograft (LNCaP) | [148] |
| SFN | ≈ PECAM-1/CD31 | TRAMP | [152] |
| SFN | ↓ Akt | Orthotopic assay (PC3) | [147] |
| SFN | ↓ ERK1/2 | Orthotopic assay (PC3) | [147] |
| SFN | ↓ FOXO3a | Orthotopic assay (PC3) | [147] |
| SFN | ↓ HIF-1 α | Orthotopic assay (PC3) | [147] |
| SFN | ↓ IL-6 | Orthotopic assay (PC3) | [147] |
| SFN | ↓ IL-8 | Orthotopic assay (PC3) | [147] |
| SFN | ↓ TGF-β1 | Orthotopic assay (PC3) | [147] |
| SFN | ↓ VEGF | Orthotopic assay (PC3) | [147] |
Abbreviations: ≈, no change in expression; ↓, reduced expression; ERK1/2, extracellular signal-regulated kinase 1/2; FOXO3a, forkhead box O3; HIF-1α, hypoxia-inducible factor 1-alpha; IL, interleukin; PECAM-1/CD31, tumor platelet/endothelial cell adhesion molecule; PEITC, phenethyl isothiocyanate; SFN, sulforaphane; TGF-β1, transforming growth factor-β1; TRAMP, transgenic adenocarcinoma of the mouse prostate model; VEGF, vascular endothelial growth factor.